Personalised medicine in patients receiving biologic medicine

The biomarker assay will operate on a small blood-testing device for home-use, named Trace™, which enables patients to retrieve information about the level of medicine and possibly neutralising antibodies within 15 minutes from home, all by themselves.

The project will make a significant contribution to the development of personalised medicine in patients treated with biologic medicine by enabling a more accurate dispensation of medicine. The impact will be that physicians and patients may optimise patients’ medical treatment, thereby ensuring a more optimal use of healthcare resources.

The total funding for the project is € 1,348,000, which roughly equals kr. 10,000,000

The Parker Institutes share is € 190,000, which roughly equals kr. 1,400,000

See further details about the Trace™ platform at

See further details in the official press release from Innovation Fund Denmark at"